No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Perspectum Partners with UT Southwestern Medical Center on Dallas Heart & Minds Study

Editor: What To Know

  • “As part of our efforts to improve the care of patients, we are using LiverMultiScan to assess the liver in this large DHMS cohort hoping to further our understanding of obesity phenotyping in the liver.
  • In the previous examinations, we extensively characterized obesity and cardiometabolic risk factors in our cohort – we are about to gain critical knowledge of how long-standing obesity and metabolic syndrome can affect liver health using LiverMultiScan by Perspectum.
  • Perspectum reports the DHMS initial aim was to improve the diagnosis, prevention and treatment of heart disease, over the years this has expanded to encompass metabolic diseases, such as fatty liver disease.

Perspectum has announced a collaboration with UT Southwestern Medical Center, to include LiverMultiScan® technology in the Dallas Heart & Minds Study (DHMS).

Perspectum reports the DHMS initial aim was to improve the diagnosis, prevention and treatment of heart disease, over the years this has expanded to encompass metabolic diseases, such as fatty liver disease.

LiverMultiScan’s quantitative MRI technology will be used to measure chronic liver disease, enabling a deeper understanding of the interactions between genetics, environment and lifestyle on the health of the liver.

LiverMultiScan is currently being used across Dallas, and the US, to enable physicians to better diagnose and treat patients with disorders such as Fatty Liver Disease. Using a non-invasive MRI, the test gives metrics of liver tissue health that correlate with inflammation, fibrosis, fat, and iron.

“We are really excited to work with Perspectum on the Dallas Hearts and Minds Study, formerly known as Dallas Heart Study. In the previous examinations, we extensively characterized obesity and cardiometabolic risk factors in our cohort – we are about to gain critical knowledge of how long-standing obesity and metabolic syndrome can affect liver health using LiverMultiScan by Perspectum.” Dr. Jaret Berry, Principal Investigator, Dallas Heart and Minds Study

“As part of our efforts to improve the care of patients, we are using LiverMultiScan to assess the liver in this large DHMS cohort hoping to further our understanding of obesity phenotyping in the liver.” – Dr. Carlos Duncker, Medical Science Liaison, Perspectum.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy